Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
IRIX 
IRIDEX Corporation (IRIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: IRIX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -34.22% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.39M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 78923 | Beta 0.61 | 52 Weeks Range 0.78 - 2.41 | Updated Date 06/18/2025 |
52 Weeks Range 0.78 - 2.41 | Updated Date 06/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.43 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-06-18 | When After Market | Estimate -0.12 | Actual -0.1008 |
Profitability
Profit Margin -14.61% | Operating Margin (TTM) -1.72% |
Management Effectiveness
Return on Assets (TTM) -9.54% | Return on Equity (TTM) -106.93% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 20446128 | Price to Sales(TTM) 0.32 |
Enterprise Value 20446128 | Price to Sales(TTM) 0.32 | ||
Enterprise Value to Revenue 0.28 | Enterprise Value to EBITDA -3.61 | Shares Outstanding 16789000 | Shares Floating 11138344 |
Shares Outstanding 16789000 | Shares Floating 11138344 | ||
Percent Insiders 27.73 | Percent Institutions 18.76 |
Analyst Ratings
Rating - | Target Price 2 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
IRIDEX Corporation
Company Overview
History and Background
IRIDEX Corporation, founded in 1989, develops, manufactures, and markets innovative laser-based medical products for the treatment of glaucoma and other ophthalmic diseases. The company has evolved from focusing on industrial lasers to specializing in medical applications.
Core Business Areas
- Glaucoma: IRIDEX offers MicroPulse Transscleral Laser Therapy (TLT) and Cyclo G6 laser systems for treating glaucoma.
- Retinal: IRIDEX provides laser systems for treating retinal diseases like diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR).
Leadership and Structure
The leadership team consists of the CEO, CFO, and other key executives. The organizational structure is typically functional, with departments like R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Cyclo G6 Glaucoma Laser System: The Cyclo G6 system delivers MicroPulse TLT for glaucoma treatment. Market share data specific to Cyclo G6 is not readily available but IRIDEX is a key player in laser glaucoma treatment. Competitors include Lumenis and Ellex (acquired by Ellex).
- IQ 577 Laser System: The IQ 577 laser system is used for retinal and glaucoma procedures. Market share data specific to IQ 577 is not readily available. Competitors include Topcon, Nidek and Quantel Medical.
Market Dynamics
Industry Overview
The ophthalmic laser market is driven by the increasing prevalence of glaucoma and retinal diseases due to aging populations and diabetes. Technological advancements and minimally invasive procedures are also key trends.
Positioning
IRIDEX is positioned as a provider of innovative laser solutions for ophthalmic diseases, particularly in the glaucoma and retinal markets. Their MicroPulse technology is a key differentiator.
Total Addressable Market (TAM)
The global ophthalmic laser market is estimated to be in the billions of dollars. IRIDEX is positioned to capture a portion of this TAM through its glaucoma and retinal product offerings.
Upturn SWOT Analysis
Strengths
- Innovative MicroPulse technology
- Established presence in the ophthalmic laser market
- Strong brand reputation within specialized segments
- Proprietary technology platforms
Weaknesses
- Limited financial resources compared to larger competitors
- Dependence on specific product lines
- Vulnerability to regulatory changes and reimbursement policies
Opportunities
- Expanding into emerging markets
- Developing new applications for MicroPulse technology
- Acquiring complementary technologies or businesses
- Strategic alliances and partnerships
Threats
- Competition from larger ophthalmic device companies
- Technological obsolescence
- Economic downturns impacting healthcare spending
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- LMN (Lumenis Be Ltd.)
- TOP (Topcon Corp.)
- ALGN (Align Technology, Inc. - acquired vision company of ELLEX MEDICAL)
Competitive Landscape
IRIDEX faces competition from larger, more established companies with broader product portfolios. IRIDEX's advantage lies in its innovative MicroPulse technology and focused approach to specific ophthalmic markets.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been mixed, with periods of rapid expansion followed by slower growth due to market conditions and competition.
Future Projections: Analyst estimates vary, but generally project moderate growth driven by increased adoption of MicroPulse TLT and expansion into new markets.
Recent Initiatives: Recent initiatives include expanding sales and marketing efforts, developing new products based on MicroPulse technology, and pursuing strategic partnerships.
Summary
IRIDEX is a player in the ophthalmic laser market with a focus on glaucoma and retinal treatments. The company's MicroPulse technology provides a competitive advantage, but limited financial resources and competition pose challenges. Growth opportunities exist in emerging markets and new applications of their core technology. Monitoring competitor activity and adapting to reimbursement changes are crucial.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Analyst Reports
- Industry Publications
- SEC Filings
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is estimated and may vary. Financial performance data should be verified through official company filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About IRIDEX Corporation
Exchange NASDAQ | Headquaters Mountain View, CA, United States | ||
IPO Launch date 1996-02-15 | CEO, President & Director Mr. Patrick Mercer | ||
Sector Healthcare | Industry Medical Devices | Full time employees 93 | Website https://www.iridex.com |
Full time employees 93 | Website https://www.iridex.com | ||
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.